{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:47:28Z","timestamp":1794674848428,"version":"4.9.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,11,10]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) is increasingly prevalent and over 99% of drugs developed for AD have failed in clinical trials. A growing body of literature suggests that potent inhibitors of tumor necrosis factor-\u03b1 (TNF-\u03b1) have potential to improve cognitive performance. Objective: In this review, we summarize the evidence regarding the potential for TNF-\u03b1 inhibition to prevent AD and improve cognitive function in people at risk for dementia. Methods: We conducted a literature review in PubMed, screening all articles published before July 7, 2019 related to TNF blocking agents and curcumin (another TNF-\u03b1 inhibitor) in the context of AD pathology. The keywords in the search included: AD, dementia, memory, cognition, TNF-\u03b1, TNF inhibitors, etanercept, infliximab, adalimumab, golimumab, and curcumin. Results: Three large epidemiology studies reported etanercept treated patients had 60 to 70% lower odds ratio (OR) of developing AD. Two small-randomized control trials (RCTs) demonstrated an improvement in cognitive performance for AD patients treated with etanercept. Studies using animal models of dementia also reported similar findings with TNF blocking agents (etanercept, infliximab, adalimumab, Theracurmin), which appeared to improve cognition. A small human RCT using Theracurmin, a well-absorbed form of curcumin that lowers TNF-\u03b1, showed enhanced cognitive performance and decreased brain levels of amyloid-\u03b2 plaque and tau tangles. Conclusion: TNF-\u03b1 targeted therapy is a biologically plausible approach to the preservation of cognition, and warrants larger prospective RCTs to further investigate potential benefits in populations at risk of developing AD.<\/jats:p>","DOI":"10.3233\/jad-200711","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T16:16:24Z","timestamp":1601396184000},"page":"619-626","source":"Crossref","is-referenced-by-count":126,"title":["Therapeutic Potential of TNF-\u03b1 Inhibition for Alzheimer\u2019s Disease Prevention"],"prefix":"10.1177","volume":"78","author":[{"given":"Noel","family":"Torres-Acosta","sequence":"first","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"O\u2019Keefe","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan L.","family":"O\u2019Keefe","sequence":"additional","affiliation":[{"name":"Tulane Medical Center, New Orleans, LA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Prevention Clinic, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Small","sequence":"additional","affiliation":[{"name":"UCLA Longevity Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200711_ref1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12491","article-title":"Lessons learned from Alzheimer disease: Clinical trials with negative outcomes","volume":"11","author":"Cummings","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.3233\/JAD-200711_ref2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200711_ref3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fneur.2018.01179","article-title":"Alzheimer\u2019s \u201cprevention\u201d vs. \u201crisk reduction\u201d: Transcending semantics for clinical practice","volume":"9","author":"Hodes","year":"2018","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-200711_ref4","first-page":"699","article-title":"Dementia (including Alzheimer\u2019s disease) can be prevented: Statement supported by international experts","volume":"38","author":"Smith","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200711_ref5","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.3233\/JAD-200711_ref6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010-2015","volume":"26","author":"Mehta","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/JAD-200711_ref7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-200711_ref8","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMe1903193","article-title":"Lowering of amyloid-beta by beta-secretase inhibitors - some informative failures","volume":"380","author":"Knopman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-200711_ref9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1567205013666160930110551","article-title":"Targeting tumor necrosis factor alpha for Alzheimer\u2019s disease","volume":"14","author":"Decourt","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-200711_ref10","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/bph.12131","volume":"169","author":"Aggarwal","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.3233\/JAD-200711_ref11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-alpha signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.3233\/JAD-200711_ref12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNF alpha and the TNF receptor superfamily: Structure-function relationship(s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc Res Tech"},{"key":"10.3233\/JAD-200711_ref13","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-kappaB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.3233\/JAD-200711_ref14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/1872213X12666180703163824","article-title":"Role of curcumin in regulation of TNF-alpha mediated brain inflammatory responses","volume":"12","author":"Baj","year":"2018","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.3233\/JAD-200711_ref15","doi-asserted-by":"crossref","first-page":"e0229819","DOI":"10.1371\/journal.pone.0229819","article-title":"Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer\u2019s disease in patients with rheumatoid arthritis and psoriasis","volume":"15","author":"Zhou","year":"2020","journal-title":"PLoS One"},{"key":"10.3233\/JAD-200711_ref16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40263-016-0374-z","article-title":"Treatment for rheumatoid arthritis and risk of Alzheimer\u2019s disease: A nested case-control analysis","volume":"30","author":"Chou","year":"2016","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-200711_ref19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp.74.9.1200","article-title":"Intrathecal inflammation precedes development of Alzheimer\u2019s disease","volume":"74","author":"Tarkowski","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-200711_ref20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/1744666X.2018.1454835","article-title":"New therapies versus first-generation biologic drugs in psoriasis: A review of adverse events and their management","volume":"14","author":"Carrascosa","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.3233\/JAD-200711_ref22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jagp.2017.10.010","article-title":"Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial","volume":"26","author":"Small","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-200711_ref23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/alzrt146","article-title":"Oral curcumin for Alzheimer\u2019s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study","volume":"4","author":"Ringman","year":"2012","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200711_ref24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1874467211666181012150847","article-title":"Curcuminoids and novel opportunities for the treatment of Alzheimer\u2019s disease: Which molecules are actually effective?","volume":"12","author":"Zholos","year":"2019","journal-title":"Curr Mol Pharmacol"},{"key":"10.3233\/JAD-200711_ref25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","article-title":"Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial","volume":"84","author":"Butchart","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-200711_ref26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2010.01.017","article-title":"Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis","volume":"77","author":"Chen","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.3233\/JAD-200711_ref27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2377-8-27","article-title":"Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer\u2019s disease","volume":"8","author":"Tobinick","year":"2008","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-200711_ref28","first-page":"25","article-title":"TNF-alpha modulation for treatment of Alzheimer\u2019s disease: A 6-month pilot study","volume":"8","author":"Tobinick","year":"2006","journal-title":"MedGenMed"},{"key":"10.3233\/JAD-200711_ref29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.brainres.2010.10.053","article-title":"Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP\/PS1 transgenic mouse brains","volume":"1368","author":"Shi","year":"2011","journal-title":"Brain Res"},{"key":"10.3233\/JAD-200711_ref30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuint.2014.04.001","article-title":"Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice","volume":"72","author":"Detrait","year":"2014","journal-title":"Neurochem Int"},{"key":"10.3233\/JAD-200711_ref31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.acthis.2014.12.002","article-title":"Effects of systemic Thalidomide and intracerebroventricular Etanercept and Infliximab administration in a Streptozotocin induced dementia model in rats","volume":"117","author":"Kubra","year":"2015","journal-title":"Acta Histochem"},{"key":"10.3233\/JAD-200711_ref32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ptr.5030","article-title":"Therapeutic potential of turmeric in Alzheimer\u2019s disease: Curcumin or curcuminoids?","volume":"28","author":"Ahmed","year":"2014","journal-title":"Phytother Res"},{"key":"10.3233\/JAD-200711_ref33","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/aje\/kwj267","article-title":"Curry consumption and cognitive function in the elderly","volume":"164","author":"Ng","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.3233\/JAD-200711_ref34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.22203\/eCM.v033a21","article-title":"Curcumin alleviates lumbar radiculopathy by reducing neuroinflammation, oxidative stress and nociceptive factors","volume":"33","author":"Xiao","year":"2017","journal-title":"Eur Cell Mater"},{"key":"10.3233\/JAD-200711_ref35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4062\/biomolther.2019.046","article-title":"Theracurmin ameliorates cognitive dysfunctions in 5XFAD mice by improving synaptic function and mitigating oxidative stress","volume":"27","author":"Kim","year":"2019","journal-title":"Biomol Ther"},{"key":"10.3233\/JAD-200711_ref36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ptr.6257","article-title":"Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis","volume":"33","author":"Zhu","year":"2019","journal-title":"Phytother Res"},{"key":"10.3233\/JAD-200711_ref37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-200711_ref38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5483\/BMBRep.2020.53.1.309","article-title":"Peripheral inflammatory biomarkers in Alzheimer\u2019s disease: A brief review","volume":"53","author":"Park","year":"2020","journal-title":"BMB Rep"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:09Z","timestamp":1777370949000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200711"}},"subtitle":[],"editor":[{"given":"Dharma Singh","family":"Khalsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":35,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-200711","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}